Pearl River Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Pearl River Capital’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,400	Closed	-$209K	–	418
2024 Q1	$209K	Sell	1,400 -2,476	-64%	-$413K	0.03%	433
2023 Q4	$742K	Buy	+3,876	New	+$660K	0.12%	252
2022 Q4	–	Sell	-2,935	Closed	-$587K	–	498
2022 Q3	$587K	Buy	2,935 +329	+13%	+$62.8K	0.11%	263
2022 Q2	$380K	Sell	2,606 -269	-9%	-$38.2K	0.09%	307
2022 Q1	$469K	Sell	2,875 -2,026	-41%	-$309K	0.13%	240
2021 Q4	$831K	Buy	+4,901	New	+$911K	0.22%	142
2021 Q1	–	Sell	-3,070	Closed	-$399K	–	381
2020 Q4	$399K	Buy	3,070 +1,669	+119%	+$223K	0.14%	221
2020 Q3	$204K	Sell	1,401 -59	-4%	-$8.38K	0.09%	333
2020 Q2	$216K	Buy	+1,460	New	+$197K	0.11%	243

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Pearl River Capital's ALNY Position: Q2 2024 in Review

Pearl River Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2024, closing a stake of 1,400 shares — an estimated $209K sold.

Pearl River Capital first reported a position in ALNY in Q2 2020 and held it in 9 quarters. The position peaked at $831K in Q4 2021. 521 funds tracked by Wall St. Rank hold ALNY as of Q2 2024.

Pearl River Capital reported no remaining Alnylam Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Pearl River Capital sold 1,400 Alnylam Pharmaceuticals shares in Q2 2024, an estimated $209K.
Pearl River Capital first reported a position in Alnylam Pharmaceuticals in Q2 2020 and held it in 9 quarters.
Pearl River Capital's Alnylam Pharmaceuticals position peaked at $831K in Q4 2021.
521 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2024.

Based on Pearl River Capital's 13F filing for Q2 2024, filed 13 Aug 2024.